Hospital
Wellstar North Fulton Hospital, INC
Wellstar North Fulton Hospital, INC was paid $7.80M by Medicaid between Jan 2018 and Dec 2024, across 155 billing codes. Its largest line is 99284, emergency room visit (serious) — 26% of everything it billed.
33Billing provider infoWELLSTAR NORTH FULTON HOSPITAL, INC
ROSWELL, GA 30076
ROSWELL, GA 30076
33aNPI1750312997assigned 07/05/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.80M
24GClaims191,385
24DCodes billed155
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Georgia
Rank by total paid#5 of 34
Median peer was paid$23K
This provider vs. median338×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,707 | $778K | |
| 2019 | 25,253 | $879K | |
| 2020 | 21,836 | $891K | |
| 2021 | 31,391 | $1.28M | |
| 2022 | 32,742 | $1.43M | |
| 2023 | 33,300 | $1.57M | |
| 2024incomplete | 26,156 | $977K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 26% | 9,682 | 8,783 | $2.01M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 17% | 7,821 | 7,249 | $1.32M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 5,190 | 4,726 | $1.30M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.3% | 1,196 | 1,127 | $414K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.9% | 2,123 | 1,846 | $304K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.0% | 1,703 | 1,593 | $155K |
| 71046 | Radiologic examination, chest; 2 views | 1.8% | 3,053 | 2,844 | $143K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.8% | 5,104 | 4,579 | $140K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.7% | 3,108 | 2,736 | $133K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.6% | 5,014 | 4,033 | $128K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.5% | 1,230 | 1,184 | $118K |
| 80053 | Comprehensive metabolic panel | 1.2% | 12,041 | 9,805 | $96K |
143 more codes
| 71045 | Radiologic examination, chest; single view | 1.2% | 3,674 | $90K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 852 | $77K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 14,616 | $73K |
| G0378 | Hospital observation service, per hour | <1% | 1,301 | $70K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,377 | $65K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 964 | $63K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 552 | $63K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,532 | $57K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,227 | $56K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 908 | $56K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,231 | $52K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,053 | $49K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 438 | $46K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 291 | $45K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 844 | $44K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 663 | $39K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,806 | $35K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 1,678 | $34K |
| 84484 | <1% | 3,728 | $31K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 359 | $29K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,910 | $27K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,214 | $26K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,997 | $23K |
| 81025 | <1% | 3,137 | $19K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,785 | $17K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 86 | $17K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,277 | $15K |
| 83690 | <1% | 2,700 | $14K | |
| 83880 | <1% | 717 | $13K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 116 | $13K |
| 76801 | <1% | 144 | $12K | |
| 81001 | <1% | 5,175 | $12K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 621 | $12K |
| 80061 | Lipid panel | <1% | 1,527 | $12K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,709 | $12K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 675 | $11K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,189 | $11K |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,467 | $9K |
| 86901 | <1% | 1,196 | $9K | |
| 85027 | <1% | 2,670 | $8K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 159 | $8K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 300 | $6K |
| 84703 | <1% | 1,126 | $6K | |
| 83735 | <1% | 1,971 | $5K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 53 | $5K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 284 | $5K |
| 84702 | <1% | 810 | $5K | |
| 87400 | <1% | 158 | $5K | |
| 81003 | <1% | 2,544 | $4K | |
| 93975 | <1% | 60 | $4K | |
| 87077 | <1% | 657 | $4K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 2,222 | $4K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 16 | $4K |
| 82247 | <1% | 1,187 | $4K | |
| 86900 | <1% | 1,174 | $4K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,765 | $4K |
| 85610 | <1% | 1,724 | $4K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,828 | $4K |
| 87186 | <1% | 548 | $4K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 149 | $3K |
| 85730 | <1% | 1,127 | $3K | |
| 82248 | <1% | 946 | $3K | |
| 99152 | <1% | 41 | $3K | |
| 73562 | <1% | 58 | $3K | |
| 73030 | <1% | 48 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 149 | $3K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,683 | $3K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 828 | $3K |
| 80320 | <1% | 244 | $2K | |
| 83605 | <1% | 423 | $2K | |
| 82962 | <1% | 828 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,309 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,652 | $2K |
| 86850 | <1% | 241 | $2K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,668 | $2K |
| 87081 | <1% | 223 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 121 | $2K |
| 96376 | <1% | 119 | $2K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 173 | $2K |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 923 | $2K |
| 73610 | <1% | 27 | $2K | |
| 71250 | <1% | 13 | $1K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 44 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 819 | $1K |
| 85379 | <1% | 240 | $1K | |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 15 | $1K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 16 | $1K |
| 73630 | <1% | 25 | $1K | |
| 74018 | <1% | 14 | $976.43 | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 12 | $906.91 |
| 93971 | <1% | 13 | $896.24 | |
| Q3014 | Telehealth originating site facility fee | <1% | 92 | $886.36 |
| 73560 | <1% | 41 | $858.78 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 998 | $840.45 |
| 82607 | <1% | 80 | $821.31 | |
| 72100 | <1% | 27 | $809.49 | |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 13 | $799.73 |
| 87040 | <1% | 92 | $692.18 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,138 | $657.07 |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 104 | $607.81 |
| APT02 | <1% | 81 | $575.10 | |
| 82570 | <1% | 98 | $462.87 | |
| 86803 | <1% | 53 | $451.01 | |
| 87088 | <1% | 70 | $435.61 | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 59 | $425.24 |
| J3490 | Unclassified drugs | <1% | 292 | $371.12 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,788 | $369.97 |
| 80330 | <1% | 19 | $358.48 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 254 | $357.04 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 15 | $346.76 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 28 | $336.74 |
| 80076 | <1% | 73 | $334.28 | |
| 82728 | <1% | 26 | $296.22 | |
| 82565 | <1% | 124 | $293.80 | |
| 86140 | <1% | 68 | $291.22 | |
| 72170 | <1% | 12 | $280.89 | |
| 84439 | <1% | 48 | $280.74 | |
| 36416 | <1% | 280 | $244.78 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 144 | $188.41 |
| 83655 | <1% | 13 | $187.90 | |
| APT17 | <1% | 12 | $178.44 | |
| A9270 | Non-covered item or service | <1% | 3,696 | $164.50 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 22 | $160.90 |
| 82550 | <1% | 50 | $159.88 | |
| 82746 | <1% | 16 | $153.75 | |
| S0020 | Injection, bupivicaine hydrochloride, 30 ml | <1% | 66 | $106.89 |
| 80305 | <1% | 14 | $99.04 | |
| 83550 | <1% | 13 | $88.08 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 116 | $83.92 |
| 83540 | <1% | 13 | $69.90 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 47 | $68.49 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 81 | $65.60 |
| 84145 | <1% | 27 | $57.06 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 93 | $44.71 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | <1% | 35 | $40.05 |
| 85018 | <1% | 13 | $33.84 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 301 | $26.11 |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 21 | $14.82 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 46 | $14.06 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 76 | $10.33 |
| 80329 | 0% | 19 | $0.00 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 15 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBUDZINSKI, ANTHONY (EVP & CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Kennestone Hospital, INC. | Marietta, GA | $1.90M |
| Wellstar Spalding Regional Hospital, INC | Griffin, GA | $80K |
| Wellstar Atlanta Medical Center, INC | Atlanta, GA | $70K |
| Cobb Hospital, INC | Austell, GA | $43K |
| Douglas Hospital, INC. | Douglasville, GA | $2K |
| Paulding Medical Center, INC. | Hiram, GA | $1K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.